The comment period on CMS's CY2027 Medicare Physician Fee Schedule proposed rule closed two days ago — September 14, 2026. If finalized as written, the Modifier 25 change alone could strip hundreds of thousands of dollars in annual revenue from specialty practices that don't restructure their billing workflows before January 1.
This isn't an incremental tweak. CMS is proposing to cut payment by 50% when a separately identifiable E/M visit is billed on the same day as a procedure. For dermatology practices where 20–35% of billing volume involves same-day E/M + procedure combinations, this is a structural revenue threat. For ENT and orthopedic practices running complex surgical schedules, the math is equally brutal.
And the Modifier 25 cut doesn't arrive alone. It compounds with a -1.68% conversion factor reduction for non-APM participants and a Medicaid state-directed payment phase-down under the One Big Beautiful Bill Act that puts $60 billion in federal supplemental funding at risk across 37+ states.
Three simultaneous payment cuts. One billing infrastructure. Here's what specialty practices need to understand — and what to do about it before the rule takes effect.
The Modifier 25 Change: 50% Payment Cut on Same-Day E/M + Procedure
Today, Modifier 25 allows a physician to bill a separately identifiable E/M visit on the same day as a minor procedure. The visit must represent a distinct service — a separately identifiable chief complaint, history, examination, or medical decision-making component beyond what the procedure itself requires. When properly documented, both the E/M and the procedure are paid in full.
The CY2027 proposed rule changes the math fundamentally:
- If the E/M payment is lower than the procedure payment — the E/M is reduced by 50%
- If the E/M payment is higher than the procedure payment — the procedure payment is reduced by 50%
The lower-paid service in any same-day pair takes a 50% haircut. Every time.
Why Dermatology Gets Hit Hardest
Dermatology is the specialty most exposed to this change because same-day E/M + procedure billing is fundamental to how dermatology is practiced — not an edge case, but the standard workflow.
Consider a typical dermatology encounter: a patient presents for a skin check. The dermatologist identifies a suspicious lesion during the examination (E/M visit), performs a biopsy (procedure), and bills both services with Modifier 25 on the E/M. This happens dozens of times per week in most dermatology practices.
The specific combination points that generate the most exposure:
- Mohs surgery + E/M visit — Mohs procedures frequently include a separately identifiable evaluation, especially when additional lesions are assessed beyond the surgical site
- Skin biopsy + office visit — The most common same-day billing pair in dermatology; patients presenting for evaluation who require diagnostic biopsy
- Cryotherapy/destruction + E/M — Ablation of actinic keratoses or warts during a visit that also addresses other dermatologic concerns
- Excision + E/M — Lesion removal combined with evaluation of other skin conditions during the same encounter
At 20–35% of total billing volume in same-day E/M + procedure combinations, a 50% cut on the lower service translates to roughly $40–$80 in lost revenue per affected encounter. Across 4,000–6,000 affected encounters per year in a mid-size dermatology practice, that's a potential $160,000–$480,000 annual revenue loss — from a single rule change.
ENT, Orthopedics, and Surgical Specialties: The Compounding Effect
Dermatology absorbs the highest-volume impact, but ENT and orthopedic practices face compounding pressures:
ENT-Specific Exposure
ENT practices routinely bill E/M visits with nasal endoscopy, audiometry, allergy testing, and in-office procedures. Septoplasty evaluations, sinus procedure assessments, and ear tube consultations all involve same-day E/M + procedure billing. The specialty's multi-facility complexity — office, ASC, hospital outpatient — adds authorization and facility-specific payment variability on top of the Modifier 25 cut.
Orthopedic-Specific Exposure
The American Association of Orthopaedic Surgeons warned that the CY2027 changes would cause "irreparable damage by instituting acute cuts to orthopedic care that will change the face of American healthcare indefinitely." Orthopedic practices bill same-day E/M with joint injections, fracture care, and surgical evaluations. The proposed Modifier 25 change stacks on top of the Indirect Practice Cost Index (IPCI) elimination being phased in over two years — hitting high-overhead surgical specialties from both directions.
The Triple Pressure: Modifier 25 + Conversion Factor + OBBBA
The Modifier 25 cut doesn't arrive in isolation. Three payment pressures converge on January 1, 2027:
| Payment Change | Impact | Effective |
|---|---|---|
| Modifier 25 — 50% cut on lower service | $160K–$480K annual loss (mid-size derm) | January 1, 2027 |
| Conversion factor — -1.68% (non-APM) | Across-the-board rate reduction | January 1, 2027 |
| OBBBA Medicaid SDP phase-down | $60B federal funding at risk, 37+ states | Begins 2028 |
The OBBBA Medicaid Risk
The One Big Beautiful Bill Act limits Medicaid state-directed payments (SDPs) to 110% of Medicare rates in non-expansion states and 100% of Medicare in expansion states. Currently, SDPs can supplement Medicaid claims up to average commercial rates — a significant revenue source for practices with substantial Medicaid patient panels.
The KFF analysis of excess state-directed payments reveals the scale of the problem:
- California: $7.4 billion in excess SDP
- Illinois: $4.0 billion
- Kentucky: $3.9 billion
- Texas: $3.5 billion
- North Carolina: $3.4 billion
- Louisiana: $3.3 billion
- Arizona: $3.0 billion
- Michigan: $2.6 billion
The phase-down begins in 2028 with 10-percentage-point annual increments. Practices that depend on Medicaid supplemental payments have 18 months to prepare — but the financial modeling needs to start now, while the Modifier 25 response is being planned.
What G2211 Does (and Doesn't Do) for Specialists
The CY2027 proposed rule shifts G2211 — the longitudinal care add-on code — from a flat payment to 16% of the E/M service value (32% for qualifying ACO participants). This change benefits primary care and behavioral health physicians who manage ongoing patient relationships.
For procedural specialists, G2211 provides minimal offset:
- Dermatology, ENT, and orthopedic encounters are typically episodic or procedural, not longitudinal care relationships that qualify for G2211
- ACO participation — which doubles the G2211 percentage — is uncommon among procedural specialty practices
- Even where G2211 applies, the 16% add-on doesn't compensate for a 50% reduction on the lower service in a same-day E/M + procedure pair
The budget neutrality math is explicit: primary care and behavioral health gains are funded by cuts to procedural and high-resource specialties. G2211 is part of the mechanism that shifts payment away from surgical specialties. It's not a lifeline for dermatology or ENT.
How AI Billing Automation Prepares Practices for January 1
The practices that will absorb the CY2027 changes with the least revenue disruption are the ones that audit, model, and restructure their billing workflows before the rule takes effect. AI billing automation addresses each layer of the preparation:
1. Real-Time Modifier 25 Eligibility Checking
AI analyzes each claim before submission to verify that the E/M documentation meets the separately identifiable condition requirement. Under the new payment structure, every Modifier 25 claim must justify its documentation more rigorously — because payers will use the reduced payment as an enforcement lever to deny claims where documentation is borderline. AI verifies HPI, ROS, exam, and MDM elements are distinct from the procedure documentation before the claim leaves the practice.
2. Per-Encounter Revenue Modeling
AI models the revenue impact of each same-day E/M + procedure combination under the proposed payment structure. Practices can see — at the encounter level — exactly how much revenue shifts under the new rule and where documentation or coding changes could minimize losses. This analysis converts an abstract policy change into specific, actionable revenue projections per provider and per procedure combination.
3. Payer-Mix Analysis for OBBBA Exposure
AI runs payer-mix analysis across the practice's entire patient panel to quantify Medicaid-dependent revenue at risk from the OBBBA phase-down. Practices in Texas, California, Illinois, and other high-exposure states can model the 2028–2030 phase-down impact and develop commercial-payer conversion strategies before the cuts begin.
4. Conversion Factor Fee Schedule Updates
AI automates the fee schedule recalculation across all contracted rates when the conversion factor drops -1.68%. Manual fee schedule updates create lag — claims submitted at outdated rates generate underpayments that compound across the payer mix. AI applies the new conversion factor across every CPT-payer combination simultaneously, eliminating the recalculation delay.
5. Documentation Completeness Verification
Under the current system, borderline Modifier 25 documentation sometimes survives payer review because the financial stakes are lower. Under a 50% payment reduction, payers have stronger incentive to audit Modifier 25 claims. AI documentation verification catches insufficiency before submission — ensuring each separately identifiable E/M visit is documented with the clinical specificity that survives post-payment audit.
The Window Is Open. The Clock Is Running.
The CY2027 PFS comment period closed September 14. CMS will finalize the rule before January 1. The lobbying battle — AAOS's public warning, dermatology society opposition, specialty medicine coalition pressure — may produce modifications, but practices cannot plan on the rule being withdrawn entirely.
The practices that audit their Modifier 25 billing exposure now — identifying which procedure-E/M combinations generate the most revenue at risk, modeling the per-encounter impact, and restructuring documentation and workflow standards — will absorb the change. The practices that wait for finalization will be scrambling in November.
AI billing automation turns this from a reactive scramble into a proactive restructuring. Audit your Modifier 25 exposure, model your conversion factor impact, and quantify your Medicaid SDP risk — before January 1 makes the math permanent.